Sign up
Pharma Capital

Arix Bioscience forms collaboration with Evotec AG and prominent cancer research center

Arix Bioscience Plc (LON:ARIX) Chairman Jonathan Peacock and Investment Director Daniel O'Connell tell Proactive Investors the health care and life science company has formed LAB591, an academic "BRIDGE" collaboration with the Fred Hutchinson Cancer Research Center in Seattle, Washington, and drug discovery alliance and development partnership company Evotec AG (OTCMKTS:EVTCY).

According to Arix, LAB591 aims to accelerate research discoveries at Fred Hutch and use these discoveries to form new companies focused on cancer and infectious disease drug development.


View full ARIX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.